Antibody-drug conjugate therapy in a renal transplant patient with bladder cancer: A case report.
Jianrong Huang, Hailin Luo, Chuance Du et al.
✦ AI-curated · Sources linked
Case in brief
A 61-year-old male renal transplant recipient developed recurrent bladder cancer while on immunosuppressive therapy. Initial treatment included transurethral resection and epirubicin instillations, but recurrence occurred. Due to renal impairment and HER2 overexpression, the patient was treated with the antibody-drug conjugate disitamab vedotin. This therapy successfully controlled the disease, demonstrating its potential as a less toxic alternative in this patient population.
Diagnostic / clinical pearl
In renal transplant patients with recurrent bladder cancer, antibody-drug conjugates may offer an effective treatment option, especially when conventional therapies are limited by renal function.
Why it matters
This case underscores the importance of considering targeted therapies in complex patient populations, particularly those with concurrent renal impairment and cancer.